Dr. Yubin Kang of Duke Cancer Institute discusses the preclinical activity of the SK-2 inhibitor ABC294640 in multiple myeloma. Dr. Kang has the lead investigator for this investigational drug in early-stage clinical research. They have now entered Phase I/II trial...